| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
1 company
Daniel Joseph Apel is Chief Financial Officer at ARWR. Daniel Joseph Apel's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $9.7M at current prices.
The ARWR filings lean toward selling, a net 13,095 shares.
Daniel Joseph Apel has 2 Form 4 filings on record from January 2026 to April 2026, all as Chief Financial Officer at Arrowhead Pharmaceuticals (ARWR), 2026.
The 4 reported transactions were 3 open-market sales and 1 stock award.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $934K.
The only open-market sale was 13,095 shares of ARWR at an average $71.35 on April 22, 2026, about $934K.